Merck presents new Januvia data at ADA conference

USA-based drug major Merck & Co says that data from a trial of its antidiabetic Januvia (sitagliptin) show that, when used as an initial therapy in combination with metformin, the drug provides significant glycemic improvement and is well tolerated by patients with type 2 diabetes. The findings were at the American Diabetes Association's 67th annual scientific sessions, held in Chicago.

Initial combination therapy shows promise

The reported results showed that twice-daily use of a combination of 50mg of Januvia plus 1,000mg metformin brought about a mean 1.8% reduction in A1C levels in treated patients over the program's 54-week duration.